
BioLamina AB bags €19m funding for expansion
The tenth investement from Lauxera Capital Partners through its Lauxera Growth I fund will be usesd by the Swedish company to expand the development...

Radiotherapy R&D partnership
French-US company Orano Med is developing Lead-212 (212Pb) Targeted Alpha Therapy, which combines the ability of biological molecules such as...

Alnylam in US$2.8bn biobucks deal with Roche
The deal, which could fetch Alnylam Pharmaceuticals Inc up to US$2.8bn if all milestones are met and marketing approval is granted, clearly marks Big...

Retinopathy: Golgi and Breye join forces
The two companies announced their collaboration, which aims to find treatment options for both early-stage diabetic retinopathy (DR) and dry-AMD...

Mogrify Ltd extends Series A financing to $46m
The additional commitment of US$10m that results in US$46m raised was made by the new lead investors Astellas Venture Management and Parkwalk...

French Carthera closes €37.5m Series B financing round
A prominent (undisclosed) investor led the round alongside the European Innovation Council Fund (EICF) and existing investors including Panakès...

Nanobiotix SA licences NBTXR3 to J&J
NBTXR3 is currently being evaluated across different solid tumour indications including NANORAY‑312, a global Phase III pivotal study in ...